Stryker Corporation $SYK Stock Holdings Boosted by Tectonic Advisors LLC

Tectonic Advisors LLC lifted its holdings in shares of Stryker Corporation (NYSE:SYK) by 69.1% in the third quarter, Holdings Channel.com reports. The fund owned 4,109 shares of the medical technology company’s stock after purchasing an additional 1,679 shares during the quarter. Tectonic Advisors LLC’s holdings in Stryker were worth $1,132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp increased its stake in Stryker by 1.2% in the second quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after acquiring an additional 183,400 shares during the period. Wellington Management Group LLP raised its position in Stryker by 0.6% in the second quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Bank of America Corp DE acquired a new position in Stryker in the second quarter worth about $1,404,284,000. Royal Bank of Canada raised its position in Stryker by 6.5% in the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Stryker by 21.8% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock worth $846,723,000 after purchasing an additional 481,175 shares during the period. 77.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Stryker news, Director Ronda Stryker sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of analyst reports. Citigroup cut their price target on shares of Stryker from $399.00 to $360.00 and set a “buy” rating for the company in a research note on Thursday, September 10th. Citizens Jmp lowered their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. Piper Sandler dropped their target price on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Barclays raised Stryker to a “strong-buy” rating in a report on Wednesday, October 7th. Finally, Raymond James Financial set a $370.00 target price on Stryker in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $369.00.

Stryker Stock Up 0.2%

Shares of NYSE:SYK opened at $307.65 on Friday. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company’s fifty day moving average is $295.23 and its 200-day moving average is $311.93. The company has a market capitalization of $118.01 billion, a PE ratio of 31.88, a P/E/G ratio of 1.98 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts predict that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is 36.48%.

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.